Compounded by decades of stagnation, there is a dire need for new treatment options for those suffering from mental illness.

Our mission is to develop novel compounds that capture the therapeutic benefits of psychedelics to fundamentally reshape the treatment of mental illness.

Gilgamesh’s AI-powered platform, ENKIDU, is accelerating the design and discovery of our new chemical entities (NCEs) which offer improved safety, tolerability, duration, and efficacy.

We are a team of passionate neuroscience experts with decades of experience within large biopharma (Pfizer, Merck, Regeneron, Biogen, Lilly), exited startups (Perception Neuroscience, Kures, Springworks Therapeutics, Biohaven) and academia (Columbia University, Harvard University, NYU, Yale, UCSD).